← Leaderboards
Isaac T Schiefer
University Of Toledo Health Sci Campus
$5,380,034
Attributed
$5,380,034
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,380,034 · 4
By mechanism
U01$2,538,810 · 1
R01$2,262,849 · 1
R21$424,875 · 1
R03$153,500 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Toledo Health Sci Campus
Same institution · by research overlap
- Bina Joe$19,103,254
- Islam Osman$992,808
- Maurice Manning$2,015,801
- Steven Loyal Britton$7,373,146
- Frank Scott Hall$153,500
Others in their field
Other Emerging Leaders on “Design”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- John E West · University Of Texas At Austin$113,883,001
- Peter K Fritschel · California Institute Of Technology$78,820,000
- Kevin Urdahl · Seattle Children'S Hospital$72,239,698
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
Research focus
DesignPharmaceutical PreparationsIn VivoAlzheimer&AposSmall MoleculeToxic EffectMediatingLeadBrainExperimental StudyPc12 CellsAnalogProteinsInsightNeuronsRoutePathway InteractionsIn VitroLearningDoseBindingPropertyLibrariesBehavioral
Grant awards (15)
Cross platform analysis of drug targets and toxicity of bath salts$556,470
U01 · FY2025 · DA · contact PI
Cross platform analysis of drug targets and toxicity of bath salts$556,470
U01 · FY2024 · DA · contact PI
Cross platform analysis of drug targets and toxicity of bath salts$389,265
U01 · FY2024 · DA · contact PI
Zebrafish Screens to Identify Agents which Reverse the Effects of Synthetic Opioids$154,500
R21 · FY2024 · DA · contact PI
Cross platform analysis of drug targets and toxicity of bath salts$556,470
U01 · FY2023 · DA · contact PI
Zebrafish Screens to Identify Agents which Reverse the Effects of Synthetic Opioids$270,375
R21 · FY2023 · DA · contact PI
Cross platform analysis of drug targets and toxicity of bath salts$480,135
U01 · FY2022 · DA · contact PI
Development of Attenuated Furoxans as Novel Therapies for Alzheimer's Disease$386,250
R01 · FY2022 · AG · contact PI
Development of Attenuated Furoxans as Novel Therapies for Alzheimer's Disease$386,250
R01 · FY2021 · AG · contact PI
Development of Attenuated Furoxans as Novel Therapies for Alzheimer's Disease$385,208
R01 · FY2020 · AG · contact PI
Development of Attenuated Furoxans as Novel Therapies for Alzheimer's Disease$383,750
R01 · FY2019 · AG · contact PI
Development of Attenuated Furoxans as Novel Therapies for Alzheimer's Disease$337,641
R01 · FY2019 · AG · contact PI
In Vivo Photoaffinity Labeling using Casper Zebrafish for Target Identification$76,750
R03 · FY2019 · DA · contact PI
Development of Attenuated Furoxans as Novel Therapies for Alzheimer's Disease$383,750
R01 · FY2018 · AG · contact PI
In Vivo Photoaffinity Labeling using Casper Zebrafish for Target Identification$76,750
R03 · FY2018 · DA · contact PI